Literature DB >> 12114711

Analysis of TGF-B and TGF-B-RII in Thyroid Neoplasms from the United States, Japan, and China.

Yoshiaki Imamura1, Long Jin, Joseph P. Grande, Chin-Yang Li, T-R. Zheng, Lori A. Erickson, Ricardo V. Lloyd.   

Abstract

Transforming growth factor B (TGF-B) has an inhibitory effect on cell proliferation in various cells and tumors, so loss of TG-B-receptor (TGF-B-R) may lead to increase proliferative activity in these tumors. We compared the expression of TGF-B and TGF-B-Rll in a group of thyroid neoplasms from the United States, Japan, and China to determine if there were differences in the expression of this growth factor or its receptors in various tumor types from different countries. A total 108 neoplastic thyroids from the United States, 42 from Japan, and 46 from China were analyzed for TGF-B1, TGF-B3, and TGF-B-Rll by in situ hybridization with riboprobes. TGF-jB-RII expression was also examined by immunohistochemistry. TGF-B1 mRNA was expressed in all neoplastic thyroids from all three countries except for one anaplasti carcinoma (ACA). TGF-B3 expression was lowest in follicular carcinomas (FCA) from all three countries (30/42; 71%). TGF-B-RII was much lower in FCA from Japan (112; 50%) and China (6/11; 55%) compared to cases from the United States (26/29; 90%). TGF-B-RII expression in papillary carcinoma (PCA) was also lower in carcinomas from Japan (21/28; 75%) and China (23/30; 77%) compared to the United States (24/25; 96%). Most ACA from the United States (25/30; 83%) and from China (3/3; 100%) were positive for TGF-B-Rll. Immunohistochemical analysis for TGF-B-RII protein expression showed the highest levels in follicular adenomas (FA) (38/38; 100%) with decreased immunoreactivity in FCA (36142; 86%). PCA (66/83; 80%), and ACA (14/33; 42%). These findings suggest that loss of TGF-B--RII may be important in thyroid tumor progression and that environmental/geographic factors may play a role in the variable expression of TGF-B--RII in thyroid malignancy.

Entities:  

Year:  1998        PMID: 12114711     DOI: 10.1007/bf02739960

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  30 in total

1.  Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase.

Authors:  H Y Lin; X F Wang; E Ng-Eaton; R A Weinberg; H F Lodish
Journal:  Cell       Date:  1992-02-21       Impact factor: 41.582

2.  TGF-beta 1 immunohistochemistry in goiter: comparison of patients with recurrence or no recurrence.

Authors:  P P Morosini; A Taccaliti; R Montironi; M Scarpelli; L Diamanti; G Simonella; V Mancini; M D Petrelli; F Mantero
Journal:  Thyroid       Date:  1996-10       Impact factor: 6.568

3.  Loss of responsiveness to transforming growth factor beta (TGFbeta) is tightly linked to tumorigenicity in a model of thyroid tumour progression.

Authors:  J P Blaydes; D Wynford-Thomas
Journal:  Int J Cancer       Date:  1996-02-08       Impact factor: 7.396

4.  Transforming growth factor beta regulates thyroid growth. Role in the pathogenesis of nontoxic goiter.

Authors:  B Grubeck-Loebenstein; G Buchan; R Sadeghi; M Kissonerghis; M Londei; M Turner; K Pirich; R Roka; B Niederle; H Kassal
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

5.  Human malignant thyroid tumors displayed reduced levels of transforming growth factor beta receptor type II messenger RNA and protein.

Authors:  D Lazzereschi; A Ranieri; G Mincione; S Taccogna; F Nardi; G Colletta
Journal:  Cancer Res       Date:  1997-05-15       Impact factor: 12.701

6.  Immunocytochemically detectable TGF-beta associated with malignancy in thyroid epithelial neoplasia.

Authors:  B Jasani; F S Wyllie; P A Wright; N R Lemoine; E D Williams; D Wynford-Thomas
Journal:  Growth Factors       Date:  1990       Impact factor: 2.511

7.  TGFB, TGFB Receptors, Ki-67, and p27(Kip)l Expression in Papillary Thyroid Carcinomas.

Authors:  Ricardo V. Lloyd; Jorge A. Ferreiro; Long Jin; Tom J. Sebo
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

Review 8.  Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression.

Authors:  J Filmus; R S Kerbel
Journal:  Curr Opin Oncol       Date:  1993-01       Impact factor: 3.645

9.  Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study.

Authors:  L D Truong; D Kadmon; B K McCune; K C Flanders; P T Scardino; T C Thompson
Journal:  Hum Pathol       Date:  1993-01       Impact factor: 3.466

10.  Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues.

Authors:  B F van der Laan; J L Freeman; S L Asa
Journal:  Thyroid       Date:  1995-02       Impact factor: 6.568

View more
  3 in total

1.  TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma.

Authors:  C Eloy; J Santos; J Cameselle-Teijeiro; P Soares; M Sobrinho-Simões
Journal:  Virchows Arch       Date:  2012-04-20       Impact factor: 4.064

2.  EGF and TGF-β1 Effects on Thyroid Function.

Authors:  Gabriella Mincione; Maria Carmela Di Marcantonio; Chiara Tarantelli; Sonia D'Inzeo; Arianna Nicolussi; Francesco Nardi; Caterina Francesca Donini; Anna Coppa
Journal:  J Thyroid Res       Date:  2011-06-13

3.  Differential expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules; a potential diagnostic tool?

Authors:  Matthew D Brace; Jun Wang; Mark Petten; Martin J Bullock; Fawaz Makki; Jonathan Trites; S Mark Taylor; Robert D Hart
Journal:  J Otolaryngol Head Neck Surg       Date:  2014-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.